Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

Detailed price information for Medicenna Therapeutics Corp (MDNA-T) from The Globe and Mail including charting and trades.

Preliminary Phase 2 data presented in November at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting showed that a combination of AU-007 and low-dose, subcutaneous aldesleukin is ...

The third and final part of the Phase I/II trial is evaluating avelumab in combination with imneskibart and low-dose, subcutaneous aldesleukin, an IL-2 therapy. Avelumab is described as a human ...

IL-2 has proven activity against cancer, having been sold as Proleukin (aldesleukin) for kidney and skin cancers since the early 1990s, originally by Chiron and latterly by Clinigen. It is known ...

Proleukin (aldesleukin), a cancer treatment, can lead to thyroiditis, an inflammation of the thyroid gland. This occurs when the immune system targets the thyroid while fighting cancer cells.

Amylyx Pharmaceuticals has dosed the first subject in the Phase I LUMINA trial, investigating AMX0114, a potential treatment for ALS.